FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210306676> ?p ?o ?g. }

• W3210306676 endingPage "e002917" @default.
• W3210306676 startingPage "e002917" @default.
• W3210306676 abstract "Background Immune checkpoint blockade (ICB) induces durable response in approximately 20% of patients with advanced bladder urothelial cancer (aUC). Over 50% of aUCs harbor genomic alterations along the phosphoinositide 3-kinase (PI3K) pathway. The goal of this project was to determine the synergistic effects and mechanisms of action of PI3K inhibition and ICB combination in aUC. Methods Alterations affecting the PI3K pathway were examined in The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map databases. Human and mouse cells with Pten deletion were used for in vitro studies. C57BL/6 mice carrying syngeneic tumors were used to determine in vivo activity, mechanisms of action and secondary resistance of pan-PI3K inhibition, ICB and combination. Results Alterations along the PI3K pathway occurred in 57% of aUCs in TCGA. CRISPR (clustered regularly interspaced short palindromic repeats) knockout of PIK3CA induced pronounced inhibition of cell proliferation (p=0.0046). PI3K inhibition suppressed cancer cell growth, migration and colony formation in vitro. Pan-PI3K inhibition, antiprogrammed death 1 (aPD1) therapy and combination improved the overall survival (OS) of syngeneic mice with PTEN-deleted tumors from 27 days of the control to 48, 37, and 65 days, respectively. In mice with tumors not containing a PI3K pathway alteration, OS was prolonged by the combination but not single treatments. Pan-PI3K inhibition significantly upregulated CD80, CD86, MHC-I, and MHC-II in dendritic cells, and downregulated the transforming growth factor beta pathway with a false discovery rate-adjusted q value of 0.001. Interferon alpha response was significantly upregulated with aPD1 therapy (q value: <0.001) and combination (q value: 0.027). Compared with the control, combination treatment increased CD8 + T-cell infiltration (p=0.005), decreased T reg -cell infiltration (p=0.036), and upregulated the expression of multiple immunostimulatory cytokines and granzyme B (p<0.01). Secondary resistance was associated with upregulation of the mammalian target of rapamycin (mTOR) pathway and multiple Sprr family genes. Conclusions The combination Pan-PI3K inhibition and ICB has significant antitumor effects in aUC with or without activated PI3K pathway and warrants further clinical investigation. This combination creates an immunostimulatory tumor milieu. Secondary resistance is associated with upregulation of the mTOR pathway and Sprr family genes." @default.
• W3210306676 created "2021-11-08" @default.
• W3210306676 creator A5000073737 @default.
• W3210306676 creator A5002476667 @default.
• W3210306676 creator A5007000673 @default.
• W3210306676 creator A5010278316 @default.
• W3210306676 creator A5016546967 @default.
• W3210306676 creator A5018998064 @default.
• W3210306676 creator A5030938999 @default.
• W3210306676 creator A5031315906 @default.
• W3210306676 creator A5041491935 @default.
• W3210306676 creator A5052069729 @default.
• W3210306676 creator A5063124483 @default.
• W3210306676 creator A5065302418 @default.
• W3210306676 creator A5073123534 @default.
• W3210306676 creator A5086377159 @default.
• W3210306676 creator A5089238735 @default.
• W3210306676 date "2021-11-01" @default.
• W3210306676 modified "2023-10-18" @default.
• W3210306676 title "Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer" @default.
• W3210306676 cites W1555100819 @default.
• W3210306676 cites W1611944043 @default.
• W3210306676 cites W1750701169 @default.
• W3210306676 cites W2003984225 @default.
• W3210306676 cites W2012513037 @default.
• W3210306676 cites W2034213169 @default.
• W3210306676 cites W2041560123 @default.
• W3210306676 cites W2074604431 @default.
• W3210306676 cites W2076380975 @default.
• W3210306676 cites W2082839348 @default.
• W3210306676 cites W2093608608 @default.
• W3210306676 cites W2101562875 @default.
• W3210306676 cites W2104065243 @default.
• W3210306676 cites W2107601804 @default.
• W3210306676 cites W2129909745 @default.
• W3210306676 cites W2162813066 @default.
• W3210306676 cites W2169450835 @default.
• W3210306676 cites W2201379305 @default.
• W3210306676 cites W2510626203 @default.
• W3210306676 cites W2527347986 @default.
• W3210306676 cites W2552470435 @default.
• W3210306676 cites W2558903163 @default.
• W3210306676 cites W2588916311 @default.
• W3210306676 cites W2591872758 @default.
• W3210306676 cites W2611933383 @default.
• W3210306676 cites W2625852679 @default.
• W3210306676 cites W2729141564 @default.
• W3210306676 cites W2741508285 @default.
• W3210306676 cites W2744377419 @default.
• W3210306676 cites W2750320760 @default.
• W3210306676 cites W2785803176 @default.
• W3210306676 cites W2795539529 @default.
• W3210306676 cites W2802142055 @default.
• W3210306676 cites W2804923662 @default.
• W3210306676 cites W2889646458 @default.
• W3210306676 cites W2892231486 @default.
• W3210306676 cites W2895926103 @default.
• W3210306676 cites W2900710696 @default.
• W3210306676 cites W2901878811 @default.
• W3210306676 cites W2937823726 @default.
• W3210306676 cites W2943112883 @default.
• W3210306676 cites W2964014383 @default.
• W3210306676 cites W2964434768 @default.
• W3210306676 cites W2996397516 @default.
• W3210306676 cites W2997593504 @default.
• W3210306676 cites W3035973123 @default.
• W3210306676 cites W3044473529 @default.
• W3210306676 cites W3044762644 @default.
• W3210306676 cites W3087464965 @default.
• W3210306676 cites W3093130512 @default.
• W3210306676 cites W3119005666 @default.
• W3210306676 cites W3127912627 @default.
• W3210306676 cites W3157821912 @default.
• W3210306676 cites W4251731689 @default.
• W3210306676 doi "https://doi.org/10.1136/jitc-2021-002917" @default.
• W3210306676 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8562536" @default.
• W3210306676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34725212" @default.
• W3210306676 hasPublicationYear "2021" @default.
• W3210306676 type Work @default.
• W3210306676 sameAs 3210306676 @default.
• W3210306676 citedByCount "22" @default.
• W3210306676 countsByYear W32103066762022 @default.
• W3210306676 countsByYear W32103066762023 @default.
• W3210306676 crossrefType "journal-article" @default.
• W3210306676 hasAuthorship W3210306676A5000073737 @default.
• W3210306676 hasAuthorship W3210306676A5002476667 @default.
• W3210306676 hasAuthorship W3210306676A5007000673 @default.
• W3210306676 hasAuthorship W3210306676A5010278316 @default.
• W3210306676 hasAuthorship W3210306676A5016546967 @default.
• W3210306676 hasAuthorship W3210306676A5018998064 @default.
• W3210306676 hasAuthorship W3210306676A5030938999 @default.
• W3210306676 hasAuthorship W3210306676A5031315906 @default.
• W3210306676 hasAuthorship W3210306676A5041491935 @default.
• W3210306676 hasAuthorship W3210306676A5052069729 @default.
• W3210306676 hasAuthorship W3210306676A5063124483 @default.
• W3210306676 hasAuthorship W3210306676A5065302418 @default.
• W3210306676 hasAuthorship W3210306676A5073123534 @default.
• W3210306676 hasAuthorship W3210306676A5086377159 @default.

• next